MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI(TM) With New Drug Application Acceptance From The FDA. Mannkind's insulin inhaler Alfrezza since approval 7 years ago has not been a game changer for the company's revenue and bottom line although has marginally increase on monthly and yearly basics, the recent news I believe is the catalyst for MNKD to move into the next chapter for it's long term survival and it's stock price appreciation. I see the stock double in value by the approval date for Tyvaso expected by end of October 2021 to around $10 and once approved it should shoot to around $18.